Connect with us

Business

Novo Nordisk boosts lobbying as it seeks Medicare coverage for obesity drugs on August 22, 2023 at 10:00 am Business News | The Hill

Published

on

Novo Nordisk, the maker of the weight loss drug Wegovy and diabetes medication Ozempic, went on a federal lobbying spending spree in the first six months of 2023.

The Danish drugmaker is pushing Congress to pass a bill that would nix Medicare restrictions on covering weight management treatments.

Novo Nordisk has hired three new lobbying firms over the past three months, all of which disclosed being solely focused on issues related to obesity and Medicare coverage of anti-obesity drugs.

A 2003 law excludes weight-loss drugs from coverage under Medicare, the federal program that provides health coverage for older Americans. But since the American Medical Association recognized obesity as a disease in 2013, momentum has been building to shift federal policy.

Advertisement

“When Congress created the Medicare Part D drug benefit in 2003 the medical community’s understanding of obesity was in its infancy,” Nicole Ferreira, senior manager of corporate communications at Novo Nordisk, told The Hill in a written statement.

“Since then, the science has advanced, and we have learned obesity is a chronic, treatable disease — not simply a behavioral issue,” Ferreira wrote.

Sens. Tom Carper (D-Del.) and Bill Cassidy (R-La.) and Reps. Raul Ruiz (D-Calif.) and Brad Wenstrup (R-Ohio) reintroduced the Treat and Reduce Obesity Act, which would expand coverage of weight management medication to qualifying Medicare beneficiaries, before the August recess.

Novo Nordisk lobbies up

While the Treat and Reduce Obesity Act has stalled each time it’s been reintroduced over the last decade, drugmakers are capitalizing on several new factors to plead their case.

Advertisement

Public demand for the weight-loss drug is high and initial clinical trials recently suggested Wegovy reduces the risk of serious heart problems.

Qualifying federal employees are also now eligible for anti-obesity medication coverage, the U.S. Office of Personnel Management clarified in January.

“We recognize the progress made in covering anti-obesity medications; our goal is to have all Carriers offer adequate coverage,” the guidance reads.

From January through June 2023, Novo Nordisk spent nearly $2.9 million on federal lobbying for a range of policy issues including obesity drug coverage and the Treat and Reduce Obesity Act, according to federal lobbying data analyzed by the money-in-politics group OpenSecrets.

Advertisement

There are more lobbyists than ever on the Novo Nordisk payroll.

Sixty-three lobbyists, 44 of whom have swung through the so-called “revolving door” between the private sector and the government, registered to lobby on behalf of the drug maker in the first half of 2023, according to OpenSecrets data.

Novo Nordisk had 50 total lobbyists in 2022 and 28 in 2019.

Since the end of June, two new lobbying firms registered three new lobbyists to work on issues related to obesity on behalf of Novo Nordisk.

Advertisement

One of the new lobbyists is Bill Ghent, a member of the Subject Matters government relations team and former chief of staff to Carper, the bill’s lead sponsor. Ghent was Carper’s legislative director when the senator first introduced the bill in 2012. 

Ghent did not return The Hill’s request for comment.

Shortages, cost concerns could derail momentum

Questions of cost and supply constraints are clouding the hype surrounding these new drugs.

The demand has not only made it harder for people to access the anti-obesity drug, but also for patients with diabetes to access the medication they need.

Advertisement

Wegovy and Ozempic are both injections that contain semaglutide, although the dosage per pen and regulator-approved uses differentiate the drugs.

The Food and Drug Administration (FDA) approved Ozempic to treat type 2 diabetes in 2017 and the higher-dose Wegovy for weight loss in 2021.

Although Ozempic has not been approved for weight loss, it’s sometimes prescribed off-label — meaning for a purpose outside the one approved by the FDA — as demand for weight loss drugs soars. But off label usage is often not covered by insurers.

Demand for the drug has also outpaced supply, leading the FDA to note that Wegovy and Ozempic semaglutide injections are “currently in shortage.”

Advertisement

“We understand how frustrating this situation is for the communities we serve and appreciate everyone’s patience as we continue to navigate significant demand for Wegovy,” Ferreira said.

“Please know that our commitment to the obesity community is a long-term one and we are investing significantly to build capacity to meet this increasing demand.”

Could Medicare coverage help pricing?

It’s unclear how expanded Medicare coverage would impact already-high demand.

There’s also an ongoing debate on the cost of covering anti-obesity treatments, as the Congressional Budget Office has yet to officially score the Treat and Reduce Obesity Act.

Advertisement

Researchers at Vanderbilt University Medical Center estimated that covering new anti-obesity medications for just 10 percent of Medicare beneficiaries could cost the federal program up to $26.8 billion per year and drive up premiums for drug plans.

But a study by the USC Schaeffer Center for Health Policy and Economics found Medicare coverage for obesity treatments could generate up to $245 billion in savings in the first 10 years, in part due to reducing co-morbidities associated with obesity, including heart attack and stroke.

“We’ve had to talk about things as so black and white, as either don’t cover it at all or give it to everybody, and I think that there is a middle ground,” Alison Sexton Ward, a research scientist with a doctorate in applied economics who worked on the study, told The Hill in an interview.

“A lot of this conversation is being lost by the list price,” Ward added.

Advertisement

Wegovy is prohibitively expensive without insurance, with the list price topping $1,300 per month. While most patients won’t pay the full list price after rebates or insurance, prices are up to 10 times higher in the U.S. than in other peer nations, a recent analysis by KFF found.

Many rebates also only apply to users who actually have diabetes.

“Novo Nordisk believes the most effective way for the millions of Americans who need anti-obesity medicines to be able to access and afford them is to ensure these medicines are covered by government and commercial insurance plans,” Ferreira said.

Health trade groups rally behind bill

A constellation of organizations including the American Diabetes Association (ADA), Weight Watchers and the Obesity Action Coalition are backing the bill.

Advertisement

“The ADA urges swift Congressional passage of this legislation so older Americans can access the services and treatment to reduce their risk for obesity and diabetes and improve their health,” said Lisa Murdock, the ADA’s chief advocacy officer, in a written statement.

The National Kidney Foundation, American Gastroenterological Association (AGA) and Academy of Nutrition and Dietetics are among the bill’s supporters that reported lobbying work on the bill during the first half of 2023, ahead of its reintroduction.

“Because many private insurance companies model their health benefits to reflect Medicare, the passage of the bipartisan TROA could lead to improved obesity care options for all Americans,” Dr. Rotonya Carr, chair of the AGA Government Affairs Committee, told The Hill in a written statement.

“The AGA fully supports this legislation and has no reservations about expanding obesity care coverage to the millions of Americans who suffer with obesity and its complications,” Carr wrote.

Advertisement

Notably, the pharmaceutical industry association PhRMA has not taken a position or lobbied on the bill.

“We appreciate the focus on helping seniors access the medicines they need. As the treatment paradigm for diseases and conditions advance, it’s critical to ensure Medicare coverage policies evolve as well,” PhRMA spokesperson Nicole Longo told The Hill.

​Business, Health Care, Lobbying, Novo Nordisk, ozempic, Tom Carper, wegovy Novo Nordisk, the maker of the weight loss drug Wegovy and diabetes medication Ozempic, went on a federal lobbying spending spree in the first six months of 2023. The Danish drugmaker is pushing Congress to pass a bill that would nix Medicare restrictions on covering weight management treatments. Novo Nordisk has hired three new lobbying…  

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Google Accused Of Favoring White, Asian Staff As It Reaches $28 Million Deal That Excludes Black Workers

Published

on

Google has tentatively agreed to a $28 million settlement in a California class‑action lawsuit alleging that white and Asian employees were routinely paid more and placed on faster career tracks than colleagues from other racial and ethnic backgrounds.

How The Discrimination Claims Emerged

The lawsuit was brought by former Google employee Ana Cantu, who identifies as Mexican and racially Indigenous and worked in people operations and cloud departments for about seven years. Cantu alleges that despite strong performance, she remained stuck at the same level while white and Asian colleagues doing similar work received higher pay, higher “levels,” and more frequent promotions.

Cantu’s complaint claims that Latino, Indigenous, Native American, Native Hawaiian, Pacific Islander, and Alaska Native employees were systematically underpaid compared with white and Asian coworkers performing substantially similar roles. The suit also says employees who raised concerns about pay and leveling saw raises and promotions withheld, reinforcing what plaintiffs describe as a two‑tiered system inside the company.

Why Black Employees Were Left Out

Cantu’s legal team ultimately agreed to narrow the class to employees whose race and ethnicity were “most closely aligned” with hers, a condition that cleared the path to the current settlement.

The judge noted that Black employees were explicitly excluded from the settlement class after negotiations, meaning they will not share in the $28 million payout even though they were named in earlier versions of the case. Separate litigation on behalf of Black Google employees alleging racial bias in pay and promotions remains pending, leaving their claims to be resolved in a different forum.

What The Settlement Provides

Of the $28 million total, about $20.4 million is expected to be distributed to eligible class members after legal fees and penalties are deducted. Eligible workers include those in California who self‑identified as Hispanic, Latinx, Indigenous, Native American, American Indian, Native Hawaiian, Pacific Islander, and/or Alaska Native during the covered period.

Beyond cash payments, Google has also agreed to take steps aimed at addressing the alleged disparities, including reviewing pay and leveling practices for racial and ethnic gaps. The settlement still needs final court approval at a hearing scheduled for later this year, and affected employees will have a chance to opt out or object before any money is distributed.

H2: Google’s Response And The Broader Stakes

A Google spokesperson has said the company disputes the allegations but chose to settle in order to move forward, while reiterating its public commitment to fair pay, hiring, and advancement for all employees. The company has emphasized ongoing internal audits and equity initiatives, though plaintiffs argue those efforts did not prevent or correct the disparities outlined in the lawsuit.

For many observers, the exclusion of Black workers from the settlement highlights the legal and strategic complexities of class‑action discrimination cases, especially in large, diverse workplaces. The outcome of the remaining lawsuit brought on behalf of Black employees, alongside this $28 million deal, will help define how one of the world’s most powerful tech companies is held accountable for alleged racial inequities in pay and promotion.

Advertisement
Continue Reading

Business

Luana Lopes Lara: How a 29‑Year‑Old Became the Youngest Self‑Made Woman Billionaire

Published

on


At just 29, Luana Lopes Lara has taken a title that usually belongs to pop stars and consumer‑app founders.

Multiple business outlets now recognize her as the world’s youngest self‑made woman billionaire, after her company Kalshi hit an 11 billion dollar valuation in a new funding round.

That round, a 1 billion dollar Series E led by Paradigm with Sequoia Capital, Andreessen Horowitz, CapitalG and others participating, instantly pushed both co‑founders into the three‑comma club. Estimates place Luana’s personal stake at roughly 12 percent of Kalshi, valuing her net worth at about 1.3 billion dollars—wealth tied directly to equity she helped create rather than inheritance.

Via Facebook

Kalshi itself is a big part of why her ascent matters.

Founded in 2019, the New York–based company runs a federally regulated prediction‑market exchange where users trade yes‑or‑no contracts on real‑world events, from inflation reports to elections and sports outcomes.

As of late 2025, the platform has reached around 50 billion dollars in annualized trading volume, a thousand‑fold jump from roughly 300 million the year before, according to figures cited in TechCrunch and other financial press. That hyper‑growth convinced investors that event contracts are more than a niche curiosity, and it is this conviction—expressed in billions of dollars of new capital—that turned Luana’s share of Kalshi into a billion‑dollar fortune almost overnight.

Her path to that point is unusually demanding even by founder standards. Luana grew up in Brazil and trained at the Bolshoi Theater School’s Brazilian campus, where reports say she spent up to 13 hours a day in class and rehearsal, competing for places in a program that accepts fewer than 3 percent of applicants. After a stint dancing professionally in Austria, she pivoted into academics, enrolling at the Massachusetts Institute of Technology to study computer science and mathematics and later completing a master’s in engineering.

During summers she interned at major firms including Bridgewater Associates and Citadel, gaining a front‑row view of how global macro traders constantly bet on future events—but without a simple, regulated way for ordinary people to do the same.

submit your film

That realization shaped Kalshi’s founding thesis and ultimately her billionaire status. Together with co‑founder Tarek Mansour, whom she met at MIT, Luana spent years persuading lawyers and U.S. regulators that a fully legal event‑trading exchange could exist under commodities law. Reports say more than 60 law firms turned them down before one agreed to help, and the company then spent roughly three years in licensing discussions with the Commodity Futures Trading Commission before gaining approval. The payoff is visible in 2025’s numbers: an 11‑billion‑dollar valuation, a 1‑billion‑dollar fresh capital injection, and a founder’s stake that makes Luana Lopes Lara not just a compelling story but a data point in how fast wealth can now be created at the intersection of finance, regulation, and software.

Advertisement
Continue Reading

Business

Harvard Grads Jobless? How AI & Ghost Jobs Broke Hiring

Published

on

America’s job market is facing an unprecedented crisis—and nowhere is this more painfully obvious than at Harvard, the world’s gold standard for elite education. A stunning 25% of Harvard’s MBA class of 2025 remains unemployed months after graduation, the highest rate recorded in university history. The Ivy League dream has become a harsh wakeup call, and it’s sending shockwaves across the professional landscape.

Jobless at the Top: Why Graduates Can’t Find Work

For decades, a Harvard diploma was considered a golden ticket. Now, graduates send out hundreds of résumés, often from their parents’ homes, only to get ghosted or auto-rejected by machines. Only 30% of all 2025 graduates nationally have found full-time work in their field, and nearly half feel unprepared for the workforce. Go to college, get a good job“—that promise is slipping away, even for the smartest and most driven.​

Tech’s Iron Grip: ATS and AI Gatekeepers

Applicant tracking systems (ATS) and AI algorithms have become ruthless gatekeepers. If a résumé doesn’t perfectly match the keywords or formatting demanded by the bots, it never reaches human eyes. The age of human connection is gone—now, you’re just a data point to be sorted and discarded.

AI screening has gone beyond basic qualifications. New tools “read” for inferred personality and tone, rejecting candidates for reasons they never see. Worse, up to half of online job listings may be fake—created simply to collect résumés, pad company metrics, or fulfill compliance without ever intending to fill the role.

The Experience Trap: Entry-Level Jobs Require Years

It’s not just Harvard grads who are hurting. Entry-level roles demand years of experience, unpaid internships, and portfolios that resemble a seasoned professional, not a fresh graduate. A bachelor’s degree, once the key to entry, is now just the price of admission. Overqualified candidates compete for underpaid jobs, often just to survive.

One Harvard MBA described applying to 1,000 jobs with no results. Companies, inundated by applications, are now so selective that only those who precisely “game the system” have a shot. This has fundamentally flipped the hiring pyramid: enormous demand for experience, shrinking chances for new entrants, and a brutal gauntlet for anyone not perfectly groomed by internships and coaching.

Advertisement

Burnout Before Day One

The cost is more than financial—mental health and optimism are collapsing among the newest generation of workers. Many come out of elite programs and immediately end up in jobs that don’t require degrees, or take positions far below their qualifications just to pay the bills. There’s a sense of burnout before careers even begin, trapping talent in a cycle of exhaustion, frustration, and disillusionment.

Cultural Collapse: From Relationships to Algorithms

What’s really broken? The culture of hiring itself. Companies have traded trust, mentorship, and relationships for metrics, optimizations, and cost-cutting. Managers no longer hire on potential—they rely on machines, rankings, and personality tests that filter out individuality and reward those who play the algorithmic game best.

AI has automated the very entry-level work that used to build careers—research, drafting, and analysis—and erased the first rung of the professional ladder for thousands of new graduates. The result is a workforce filled with people who know how to pass tests, not necessarily solve problems or drive innovation.

The Ghost Job Phenomenon

Up to half of all listings for entry-level jobs may be “ghost jobs”—positions posted online for optics, compliance, or future needs, but never intended for real hiring. This means millions of job seekers spend hours on applications destined for digital purgatory, further fueling exhaustion and cynicism.

Not Lazy—Just Locked Out

Despite the headlines, the new class of unemployed graduates is not lazy or entitled—they are overqualified, underleveraged, and battered by a broken process. Harvard’s brand means less to AI and ATS systems than the right keyword or résumé format. Human judgment has been sidelined; individuality is filtered out.

Advertisement

What’s Next? Back to Human Connection

Unless companies rediscover the value of human potential, mentorship, and relationships, the job search will remain a brutal numbers game—one that even the “best and brightest” struggle to win. The current system doesn’t just hurt workers—it holds companies back from hiring bold, creative talent who don’t fit perfect digital boxes.

Key Facts:

  • 25% of Harvard MBAs unemployed, highest on record
  • Only 30% of 2025 grads nationwide have jobs in their field
  • Nearly half of grads feel unprepared for real work
  • Up to 50% of entry-level listings are “ghost jobs”
  • AI and ATS have replaced human judgment at most companies

If you’ve felt this struggle—or see it happening around you—share your story in the comments. And make sure to subscribe for more deep dives on the reality of today’s economy and job market.

This is not just a Harvard problem. It’s a sign that America’s job engine is running on empty, and it’s time to reboot—before another generation is locked out.

Continue Reading

Trending